JNJJOHNSON & JOHNSON
Pharmaceutical Preparations
- Revenue
- $94.2B
- 6.0% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $24.5B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear92% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear24% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear25% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $82.6B | $78.7B | $85.2B | $88.8B | $94.2B | 6.0% |
| Net income | $14.7B | $20.9B | $35.2B | $14.1B | $26.8B | 91% |
| Operating cash flow | $23.5B | $23.4B | $22.8B | $24.3B | $24.5B | 1.1% |
| Capex | $3.3B | $3.7B | $4.5B | $4.4B | $4.8B | 9.2% |
| Stock-based comp | $1.0B | $1.1B | $1.2B | $1.2B | $1.4B | 15% |
| Buybacks | $3.2B | $3.5B | $5.1B | $2.4B | $6.0B | 145% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $9M · 2
- Net
- −$9M
Pay vs performance
No pay-versus-performance disclosure yet.